Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
COSMO Pharmaceuticals N.V. ( (CH:COPN) ) has shared an update.
Cosmo Pharmaceuticals has made significant strides in its ESG initiatives, achieving an upgrade in its MSCI ESG rating to ‘A’ and doubling its LSEG ESG score, reflecting its commitment to sustainability. By joining the UN Global Compact and committing to the Science Based Targets Initiative, Cosmo positions itself as a leader in sustainable healthcare, aligning its operations with global standards and attracting ESG-focused investments.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF133.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a life-science company specializing in MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing. The company develops advanced medical solutions and collaborates with leading global pharma and MedTech companies to enhance patient care. Founded in 1997, Cosmo is headquartered in Dublin, Ireland, with offices in the USA and Italy.
Average Trading Volume: 24,263
Current Market Cap: CHF1.05B
For an in-depth examination of COPN stock, go to TipRanks’ Overview page.